GlassScriptPhysician profile
Scott M Dewhirst
NPI 1659799153
$4,199.67
in general payments reported to CMS, 2019-2025
23 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,449 · 2020: $622 · 2021: $295 · 2022: $203 · 2023: $250 · 2024: $366 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,106.51 | 2021-2025 | Vraylar, Ubrelvy |
| Neurocrine Biosciences, INC. | $619.52 | 2019-2025 | |
| Allergan, INC. | $608.73 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $275.40 | 2019-2025 | Rexulti |
| Lundbeck LLC | $198.39 | 2019-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $161.99 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $136.93 | 2019-2021 | |
| Brainsway USA INC | $135.97 | 2025 | Deep Tms |
| Teva Pharmaceuticals USA, INC. | $126.13 | 2020-2025 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $123.70 | 2019-2025 | Spravato |
| Alkermes, INC. | $104.48 | 2024-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.40 | 2025 | Caplyta |
| Avanir Pharmaceuticals, INC. | $70.86 | 2019 | |
| Ironshore Pharmaceuticals INC. | $64.41 | 2019 | |
| Axsome Therapeutics, INC. | $63.72 | 2025 | Sunosi, Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $54.65 | 2019-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $53.78 | 2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $49.65 | 2024-2025 | Nuplazid |
| Bausch Health US, LLC | $39.38 | 2022-2025 | Aplenzin, Wellbutrin |
| Almatica Pharma LLC | $36.67 | 2025 | Loreev Xr |
| Shire North American Group INC | $33.53 | 2019 | |
| Neuronetics, INC. | $22.30 | 2019 | |
| Merck Sharp & Dohme LLC | $18.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Dewhirst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.